Prognostic value of brain natriuretic peptide in the management of patients receiving cardiac resynchronization therapy

Autor: Pietro Guida, Massimo Iacoviello, Elisabetta De Tommasi, Francesca Di Serio, Lucia Varraso, M Anaclerio, Roberta Romito, Giovanni Luzzi, Cinzia Forleo, N Pansini, Mariavittoria Pitzalis
Rok vydání: 2006
Předmět:
Zdroj: European Journal of Heart Failure. 8:509-514
ISSN: 1388-9842
DOI: 10.1016/j.ejheart.2005.10.013
Popis: Objective: To evaluate the role of brain natriuretic peptide (BNP) in predicting the progression of heart failure (HF) after cardiac resynchronization therapy (CRT). Background: It has been shown that BNP predicts the prognosis and can guide the treatment of HF. Methods: We studied 50 consecutive patients (61±10 years, 23 male) with HF (8 with ischaemic cardiomyopathy), NYHA class III, left bundle branch block, left ventricular ejection fraction (LVEF) ≤35% (mean 24±6%) who underwent CRT. All patients were taking conventional HF therapy and were clinically stable. Plasma BNP levels were evaluated by two-site dual-monoclonal immunochemiluminescent assay before, and 1 month after CRT. The predictive value of BNP was assessed using univariate and multivariate regression analyses. Results: During follow-up (mean 19±12 months), HF progression was observed in 14 patients (11 were hospitalised and 3 died after worsening of HF). Multivariate analysis showed that BNP levels before (HR: 2.07; CI: 1.19–3.62; p=0.01) and 1 month after CRT (HR: 2.23; CI: 1.26–3.94; p=0.006) were significantly related to events. At 1 month, a BNP level >91.5 pg/ml had 89% sensitivity, 59% specificity, and negative and positive predictive values of 96% and 33%, respectively, for HF progression after 12 months. Conclusions: HF patients with high BNP values after 1 month of CRT have worse prognosis during follow-up. Therefore, in these patients other therapeutic options should be considered.
Databáze: OpenAIRE